The stock of Nurix Therapeutics Inc (NASDAQ: NRIX) has decreased by -1.19 when compared to last closing price of 22.64.Despite this, the company has seen a loss of -16.72% in its stock price over the last five trading days. globenewswire.com reported 2024-11-20 that The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation
Is It Worth Investing in Nurix Therapeutics Inc (NASDAQ: NRIX) Right Now?
The stock has a 36-month beta value of 2.17. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NRIX is 68.89M, and at present, short sellers hold a 13.73% of that float. On November 22, 2024, the average trading volume of NRIX was 799.88K shares.
NRIX’s Market Performance
The stock of Nurix Therapeutics Inc (NRIX) has seen a -16.72% decrease in the past week, with a -9.73% drop in the past month, and a -6.87% fall in the past quarter. The volatility ratio for the week is 8.73%, and the volatility levels for the past 30 days are at 6.24% for NRIX. The simple moving average for the past 20 days is -11.37% for NRIX’s stock, with a 18.03% simple moving average for the past 200 days.
Analysts’ Opinion of NRIX
Many brokerage firms have already submitted their reports for NRIX stocks, with UBS repeating the rating for NRIX by listing it as a “Buy.” The predicted price for NRIX in the upcoming period, according to UBS is $35 based on the research report published on October 24, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see NRIX reach a price target of $41. The rating they have provided for NRIX stocks is “Buy” according to the report published on October 11th, 2024.
Robert W. Baird gave a rating of “Outperform” to NRIX, setting the target price at $26 in the report published on September 06th of the current year.
NRIX Trading at -8.43% from the 50-Day Moving Average
After a stumble in the market that brought NRIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.32% of loss for the given period.
Volatility was left at 6.24%, however, over the last 30 days, the volatility rate increased by 8.73%, as shares sank -11.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.09% lower at present.
During the last 5 trading sessions, NRIX fell by -16.72%, which changed the moving average for the period of 200-days by +169.84% in comparison to the 20-day moving average, which settled at $25.24. In addition, Nurix Therapeutics Inc saw 116.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRIX starting from Ring Christine, who sale 3,290 shares at the price of $25.00 back on Nov 04 ’24. After this action, Ring Christine now owns 28,084 shares of Nurix Therapeutics Inc, valued at $82,250 using the latest closing price.
CHRISTINE RING, the Officer of Nurix Therapeutics Inc, proposed sale 3,290 shares at $24.47 during a trade that took place back on Nov 04 ’24, which means that CHRISTINE RING is holding shares at $80,506 based on the most recent closing price.
Stock Fundamentals for NRIX
Current profitability levels for the company are sitting at:
- -3.43 for the present operating margin
- 0.72 for the gross margin
The net margin for Nurix Therapeutics Inc stands at -3.14. The total capital return value is set at -0.45. Equity return is now at value -57.96, with -43.07 for asset returns.
Based on Nurix Therapeutics Inc (NRIX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -15.58. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -24.56.
Currently, EBITDA for the company is -141.41 million with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 26.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.28.
Conclusion
To sum up, Nurix Therapeutics Inc (NRIX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
